Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Portal hypertension and liver lesions in chronically alcohol drinking ratsprevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine
Autore:
Prkacin, I; Separovic, J; Aralicia, G; Perovic, D; Gjurasin, M; Lovric-Bencic, M; Stancic-Rokotov, D; Staresinic, M; Anic, T; Mikus, D; Sikiric, P; Seiwerth, S; Mise, S; Rotkvic, I; Jagic, V; Rucman, R; Petek, M; Turkovic, B; Marovic, A; Sebecic, B; Boban-Blagaic, A; Kokic, N;
Indirizzi:
Univ Zagreb, Fac Med, Dept Pharmacol, Zagreb 10000, Croatia Univ Zagreb Zagreb Croatia 10000 , Dept Pharmacol, Zagreb 10000, Croatia Univ Zagreb, Fac Med, Dept Pathol, Zagreb 10000, Croatia Univ Zagreb Zagreb Croatia 10000 Med, Dept Pathol, Zagreb 10000, Croatia
Titolo Testata:
JOURNAL OF PHYSIOLOGY-PARIS
fascicolo: 1-6, volume: 95, anno: 2001,
pagine: 315 - 324
SICI:
0928-4257(200101/12)95:1-6<315:PHALLI>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
RESTRAINT STRESS; MUCOSAL DAMAGE; H-2-RECEPTOR ANTAGONISTS; ADAPTIVE CYTOPROTECTION; DOPAMINE AGONISTS; ANTIULCER AGENTS; NITRIC-OXIDE; BPC-157; ETHANOL; CYSTEAMINE;
Keywords:
portal hypertension; liver lesion; chronically alcohol drinking rats pentadecapeptide BPC 157 (PL/10, PLD/116); propranolol; prevention; reversal; ranitidine ineffective;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
50
Recensione:
Indirizzi per estratti:
Indirizzo: Sikiric, P Univ Zagreb, Fac Med, Dept Pharmacol, Salata 11,POB 916, Zagreb10000, Croatia Univ Zagreb Salata 11,POB 916 Zagreb Croatia 10000 00, Croatia
Citazione:
I. Prkacin et al., "Portal hypertension and liver lesions in chronically alcohol drinking ratsprevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine", J PHYSL-PAR, 95(1-6), 2001, pp. 315-324

Abstract

Liver lesions and portal hypertension in rats, following chronic alcohol administration, are a particular target for therapy. Portal hypertension (mmHg) assessed directly into the portal vein, and liver lesions induced by 7.28 g/kg b.w, of alcohol given in drinking water for 3 months, were counteracted by a stable gastric pentadecapeptide BPC 157. GEPPPGKPADDAGLV, M.W.1419, known to have a beneficial effect in a variety of models of gastrointestinal or liver lesions (10 mug or 10 ng/kg b.w. i.p. or i.g.) and propranolol (10 mg/kg b.w. i.g.), but not ranitidine (10 mg/kg b.w. i.g.) or saline (5 ml/kg b.w. i.p./i.g.; control). The medication (once daily) was throughout either the whole 3 months period (1) or the last month only (2) (last application 24 h before sacrifice). In the background of 7.28 g/kg/daily alcohol regimen similar lesions values were assessed in control rats following alcohol consumption, after 2 or 3 months of drinking. Both prophylactic andtherapeutic effects were shown. After a period of 2 or 3 months, in all control saline [intragastrically (i.g.) or intraperitoneally (i.p.)] treated rats, the applied alcohol regimen consistently induced a significant rise of portal blood pressure values over values noted in healthy rats. In rats that received gastric pentadecapeptide BPC 157 or propranolol the otherwise raised portal pressure was reduced to the values noted in healthy rats. Besides, a raised surface area (mum(2)) and increased circumference (mum) of hepatocyte or hepatocyte nucleus [HE staining, measured using PC-compatibileprogram ISSA (VAMS, Zagreb, Croatia)] and an advanced steatosis [scored (0-4), Oil Red staining] (on 100 randomly assigned hepatocytes per each liver), an increased liver weight, all together parallel a raised portal pressure in controls. Some of them were completely eliminated (not different from healthy rats, i.e. portal pressure, the circumference and area of hepatocytes, liver weight), while others were markedly attenuated (values less than in drinking controls, still higher than in healthy rats, i.e. circumferenceand area of hepatocytes nucleus). On the other hand, ranitidine application attenuated only steatosis development. In summary, despite continuous chronic alcohol drinking, pentadecapeptide BPC 157, and propranolol may prevent portal hypertension as well as reverse already established portal hypertension along with related liver disturbances. (C) 2001 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 14:25:08